A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases
LP0189-2318
Phase 1 other active
Quick answer
A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases for Gout flares is a Phase 1 program (other) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LEO Pharma A/S
- Indication
- Gout flares
- Phase
- Phase 1
- Modality
- other
- Status
- active